Lucid Ptb Ratio vs Price To Sales Ratio Analysis
| LUCD Stock | USD 0.79 0.02 2.60% |
Lucid Diagnostics financial indicator trend analysis is infinitely more than just investigating Lucid Diagnostics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lucid Diagnostics is a good investment. Please check the relationship between Lucid Diagnostics Ptb Ratio and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
Ptb Ratio vs Price To Sales Ratio
Ptb Ratio vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lucid Diagnostics Ptb Ratio account and Price To Sales Ratio. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Lucid Diagnostics' Ptb Ratio and Price To Sales Ratio is -0.62. Overlapping area represents the amount of variation of Ptb Ratio that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Lucid Diagnostics, assuming nothing else is changed. The correlation between historical values of Lucid Diagnostics' Ptb Ratio and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ptb Ratio of Lucid Diagnostics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Ptb Ratio i.e., Lucid Diagnostics' Ptb Ratio and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | -0.62 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Price To Sales Ratio
Price to Sales Ratio is figured by comparing Lucid Diagnostics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Lucid Diagnostics sales, a figure that is much harder to manipulate than other Lucid Diagnostics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from Lucid Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lucid Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 17.1 M, whereas Selling General Administrative is forecasted to decline to about 13.1 M.
Lucid Diagnostics fundamental ratios Correlations
Click cells to compare fundamentals
Lucid Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lucid Diagnostics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Current Liabilities | 6.3M | 15.7M | 4.3M | 8.4M | 29.4M | 30.9M | |
| Net Tangible Assets | (5.3M) | (13.5M) | (24.1M) | 19.6M | 22.5M | 23.7M | |
| Retained Earnings | (5.5M) | (13.8M) | (41.9M) | (98.1M) | (150.7M) | (143.2M) | |
| Accounts Payable | 799.1K | 2.1M | 1.5M | 1.1M | 1.1M | 1.3M | |
| Total Current Assets | 390.9K | 1.4M | 57.3M | 24.4M | 22.1M | 19.4M | |
| Common Stock | 14.1K | 14.1K | 35K | 41K | 42K | 28.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.